STOCK TITAN
  1. Home
  2. News
  3. ANGO

AngioDynamics to Participate in a Virtual Fireside Chat at the KeyBanc Life Sciences & MedTech Investor Forum

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will participate in a virtual fireside chat at the KeyBanc Life Sciences & MedTech Investor Forum at 10:00 a.m. ET on Wednesday, March 24, 2021.

A live webcast of the fireside chat will be accessible through the “Investors” section of the Company’s website at www.angiodynamics.com and will be available for replay following the event.

About AngioDynamics, Inc.

AngioDynamics, Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, peripheral vascular disease, and oncology. AngioDynamics’ diverse product lines include market-leading ablation systems, vascular access products, angiographic products and accessories, drainage products, thrombolytic products, and venous products. For more information, visit www.angiodynamics.com.

Stock ANGO logo
AngioDynamics, Inc.

NASDAQ:ANGO

ANGO Rankings

#3634 Ranked by Market Cap
#4793 Ranked by Stock Gains
N/A Ranked by Dividends

ANGO Latest News

May 6, 2024
AngioDynamics’ APEX-AV Trial Results Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism Presented at SCAI 2024 Scientific Sessions
Apr 4, 2024
AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture
Apr 4, 2024
AngioDynamics Receives 510(k) Clearance for AlphaVac F18⁸⁵ System in Treatment of PE
Apr 1, 2024
AngioDynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc.
Mar 19, 2024
AngioDynamics to Report Fiscal 2024 Third Quarter Financial Results on April 4, 2024

ANGO Stock Data

242.33M
38.86M
5%
91.34%
5.65%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
LATHAM

About ANGO

founded in 1988 in queensbury, n.y., u.s., angiodynamics is today a nasdaq-listed public company. we are a leading provider of innovative medical devices used by interventional radiologists, nephrologists and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease. our diverse product line includes market-leading radiofrequency ablation and nanoknife® systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. angiodynamics has distinguished itself as a dynamic brand in a technologically competitive, high-growth industry, through the company’s consistent ability to successfully develop and bring to market new technologies and products. angiodynamics believes it is well poised to continue that trend. looking into the future, the company plans to bring forth a continuing stream of innovations that greatly improve patie